tbuckley/cabot-search huggingface dataset:
Safety and efficacy of TQ-B3525, a novel and selective oral PI3K α/δ inhibitor, in Chinese patients with advanced malignancies: A phase I dose-escalation and expansion trial.
Authors: Huaqing Wang, Wenqi Jiang, Su Li, Yu Wang, Peng Sun, Pei Zhou, Yang Zheng, Jing Zhan, Zhiming Li
Journal: Journal of Clinical Oncology (2020)

8058 Background: TQ-B3525 is a novel and selective oral PI3K α/δ inhibitor with activity 41 and 138 folds higher than Buparlisib against PI3K α and PI3K δ in pre-clinical research. This Phase I study (NCT03510767) assessed the safety, tolerability, pharmacokinetics and antitumor activity of TQ-B3525 in Chinese patients with advanced malignancies. Methods: Patients with relapsed or refractory (R/R) lymphoma who have experienced at least two prior systemic anti-cancer treatments, and advanced solid tumor who have failed standard anti-cancer treatment, were enrolled. TQ-B3525 was administered orally from 2mg, 5mg, 10mg, 20mg once daily (qd) to 10mg, 20mg twice daily (bid). DLT was observed in the first cycle (28 days) of dose-escalation phase. Dose-expansion phase started at the dose level which objective response occurs. Results: Between June 2018 and December 2019, a total of 40 patients were enrolled, Including 27 patients with R/R lymphoma and 13 patients with advanced solid tumor. Three DLTs (both grade 3 hyperglycemia) were observed: two in the 20mg bid dose cohort and one in the 10mg bid. The common AEs of all grades were hyperglycemia (65.0%), glycosylated hemoglobin increased (35.0%) and diarrhea (32.5%). Grade 3 or 4 treatment-related AEs occurred in 11 patients (27.5%), with the most common one also being hyperglycemia (10.0%). TQ-B3525 was rapidly absorbed (T max : 1-2 h) and moderately eliminated (T 1/2 : 10-12 h). At steady state, the geometric mean AUC 0-24 and C trough of TQ-B3525 at 20mg qd were 1060.7 ± 198.6 h*ng/mL and 23.4 ± 9.5 ng/mL, which was above IC 50 (4.2 ng/ml). 23 lymphoma patients were evaluable for clinical response per 2014 Lugano Classification. The overall response rate (ORR) was 60.9% (95% CI, 38.5-80.2). The ORR at ≥10mg qd was 70.0% (14/20, [95% CI, 49.9-90.1]). For R/R FL, the ORR was 72.7% (8/11, [95% CI, 46.4-99.1]). At data cut-off (2 nd February, 2020), the median PFS for lymphoma was not reached (events rate: 33.3%). The longest duration of response at data cutoff was 11.8 months in a patient with FL. Conclusions: TQ-B3525 is well-tolerated in Chinese patients with advanced malignancies, and demonstrated high promising antitumor activity in R/R lymphoma patients. Recommended phase II dose was established at 20mg qd. A single-arm phase 2 trial of TQ-B3525 in patients with R/R FL is currently underway. Clinical trial information: NCT03510767 .
Preferences for research participation among individuals with Lynch syndrome: Findings from the HEROIC Registry.
Authors: Robin Beth Dubin, Allison Burton-Chase
Journal: Journal of Clinical Oncology (2020)

e19317 Background: AliveAndKickn, whose mission is to improve the lives of individuals and families affected by Lynch Syndrome (LS) through research and education, maintains the HEROIC Registry. It is the first-of-its-kind, patient-centric, genetic database that enables individuals to take an active role in furthering LS research. Methods: The HEROIC Registry allows patients to contribute medical information and their experiences living with LS and its associated cancers to help researchers develop new treatments, understand the various genetic mutations, and conduct further studies. It also asks individuals about their preferences for participating in different types of research studies. Results: The HEROIC Registry was launched in February of 2016. Potential participants were notified about the availability of the Registry in multiple ways, including social media and patient conferences. As of January 2020, 269 individuals have added their data to the Registry. Of those, 217 have a known LS mutation and were on average 42.5 years old at the time of diagnosis. 38% report having had a diagnosis of colorectal cancer with an average diagnosis age of 43; 23% of female respondents report having had endometrial cancer with an average diagnosis age of 48. 37% are cancer-unaffected. For interest in participating in future research, 69% are somewhat or very likely or definitely want to participate in research that involves a LS treatment, with rates ranging from 62-80% based on the delivery method of the treatment. For non-treatment studies, the percentage of individuals that are somewhat or very likely or definitely want to participate in research that involves community meetings, hospital stays, a medical procedure, wearing a device, or providing information by phone are text are 76%, 46%, 52%, 83%, and 78%, respectively. The percentage of individuals willing to donate a blood sample used to study their DNA is 95%. Conclusions: The HEROIC Registry provides a unique opportunity for health care providers and researchers to partner directly with a patient-advocacy organization for the purpose of improving LS care. It also has the benefit of including a diverse set of patients who are being seen in a variety of health care settings, which can aid in exploring research questions outside of a single institution. However, individuals show clear preferences for the types of research they are likely to participate in, a fact that should be taken into consideration when researchers are planning new studies in this population.
糖皮质激素治疗带状疱疹有效性及安全性观察
Authors: 尹光文, 何秋波, 李冬芹, 于建斌
Journal: BMJ (2005)

糖皮质激素可减轻炎症反应,减少带状疱疹后遗神经痛发生率[1],但糖皮质激素治疗该病目前尚有争论.为探讨糖皮质激素治疗带状疱疹的安全性及有效性,我们应用中小剂量地塞米松治疗带状疱疹患者44例,现报道如下。
Application of intravenous anesthesia during whole lung lavage in pulmonary alveolar proteinesis
Authors: Yan-ling Sun, Wu-zhou Wu, Xian-cheng Xu, Ju-ying Liu
Journal: BMJ (2009)

Five patients with pulmonary alveolar proteinosis admitted to Taihe hospital from 2006 to 2008, were treated by whole lung lavage under intravenous anesthesia, the clinical data were collected and analyzed retrospectively. The patients were followed up for 2 to 20 months, and their symptoms and pulmonary function were improved significantly after lung lavage treatment. Our experiences showed that lung lavage with intravenous anesthesia is the most effective treatment for pulmonary alveolar proteinosis.

Key words: 
Bronchoalveolar hvage;  Pulmonary alveolar proteinosis
Analysis of race and gender disparities in incidence-based mortality in patients diagnosed with thyroid cancer from 2000 to 2014.
Authors: Juan Cintron-Garcia, Lakshmi Priyanka Pappoppula, Ashkan Shahbandi, Takefumi Komiya, Achuta Guddati
Journal: Journal of Clinical Oncology (2020)

e18570 Background: Well-differentiated thyroid cancer has better outcomes compared to anaplastic thyroid cancer. The incidence of well-differentiated thyroid cancer is higher in women whereas it is approximately the same in both genders for anaplastic thyroid cancer. The variability of incidence-based mortality across gender in the context of race has not been studied. This study analyzes the rates of incidence-based mortality among both the genders in four racial groups. Methods: The Surveillance, Epidemiology, and End Results Database was queried to conduct a nation-wide analysis for the years 2000 to 2016. Incidence-based mortality for all stages of well-differentiated and undifferentiated thyroid cancer was queried and the results were grouped by race (Caucasian/White, African American/Black, American Indian/Alaskan native and Asian/Pacific Islander) and gender. All stages and ages were included in the analysis. T-test was used to determine statistically significant difference between various subgroups. Results: Incidence-based mortality rates (per 100000) for well-differentiated and undifferentiated thyroid cancer for all races and both the genders are shown in the table below. The incidence-based mortality rates for both genders is approximately the same despite a 2-3:1 difference in incidence. Anaplastic thyroid cancer has a higher mortality rate in Caucasian and Asian/pacific Islander women compared to men despite an equal ratio of incidence. As expected, the mortality rates of anaplastic thyroid cancer were significantly higher compared to well-differentiated cancer across all races and genders. Also, Asian/Pacific Islander women have a higher rate of mortality compared to both the genders of Caucasian and African American races. Conclusions: Incidence-based mortality for anaplastic thyroid cancer is higher in women in all races whereas there is no difference in mortality between men and women for well-differentiated thyroid cancer. This is divergent from the incidence ratios noted in these malignancies. In the context of increasing incidence of thyroid cancer for the past few decades, this data suggests that additional resources may be devoted to decreasing the disparity of mortality in this gender. [Table: see text]
系统性Castleman病合并巨噬细胞活化综合征一例
Authors: 陈炎, 陶荣芳, 陈亚蓓
Journal: BMJ (2007)

患者女,70岁.因不规则低热、水肿、腹胀、食欲减退,乏力1月余,于2006年5月24日入院.2006年3月曾因右颈淋巴结0.5 cm×0.5 cm大,行手术切除病理检查,报告为反应性淋巴结炎.4月中旬渐出现不规则低热37.6℃～38.0℃,四肢、面部水肿,腹胀,食欲差,乏力.门诊检查:贫血貌,浅表淋巴结未触及,心肺无异常,肝脾未及,腹水征(+),四肢可凹性水肿(+)。
总编导读
Authors: 邵隽一
Journal: BMJ (2008)

你我身边的亲人和朋友不乏患鼻-鼻窦炎者,因为它的确是非常多见的疾病,虽不危及生命,却直接影响到患者的生存质量,且治疗费用累加起来也相当可观.这期 一文详尽阐述了对该病的认识和处理原则,尤其在论及治疗方案时,是从基层、非耳鼻咽喉科医生和耳鼻咽喉科医生的角度分别阐述,更具针对性.鼻出血也是再常见不过的病了, 清晰地告诉我们,遇到这一急症时,医生需要快速搞清楚三点问题,这影响到治疗方案选择和疗效预测。
乏力一个月皮肤黄染一周
Authors: 陈良, 赵立宇, 张琴, 祝墡珠
Journal: BMJ (2012)

病史摘要患者,女性,56岁.因乏力1个月,皮肤黄染1周于2010年4月13日来门诊就诊.患者1个月前自觉全身乏力,无发热、胸闷、气促,无头晕、耳鸣、鼻衄,无全身肌肉酸痛,无酱油色尿,无腹痛、恶心、呕吐、呕血、黑便.1周前发现全身皮肤黄染,查肝功能:ALT 50 U/L,AST 65 U/L,总胆红素72 μmol/L,直接胆红素6μmol/L,为进一步明确黄疸原因转往上级医院.既往风湿性心瓣膜病,二尖瓣、三尖瓣狭窄病史,2005年行二尖瓣置换术(金属瓣)、三尖瓣成形术,术后长期服用华法林。
First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.
Authors: Kyriakos P. Papadopoulos, Manish Sharma, Erika Paige Hamilton, Debra L. Richardson, Graeme Hodgson, Li Zhou, Angela Volkert, Hina A. Jolin, Catherine Madigan, Michael Kelly, David A. Roth
Journal: Journal of Clinical Oncology (2020)

TPS3662 Background: SY-5609 is an oral, noncovalent, highly selective and potent inhibitor of cyclin-dependent kinase 7 (CDK7), a key regulator of 2 biological processes that play critical roles in driving tumor development: transcription and cell cycle control. Evaluation of SY-5609 as a single agent in PDX models from a range of solid tumors, including breast, ovarian, lung and colorectal tumors, revealed robust antitumor activity including complete regressions, and activity in models known to be resistant to standard of care therapy. Models with genetic alterations in RB pathway genes demonstrated deep ( &gt; 90% TGI) and sustained SY-5609-induced tumor regressions following treatment discontinuation, in contrast to models without genetic alteration in RB pathway genes, suggesting that tumor cells with aberrant cell-cycle control may be particularly sensitive to SY-5609 treatment. The study is designed to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of SY-5609, to characterize the pharmacokinetic (PK), pharmacodynamic (PD), and preliminary antitumor activity of SY-5609, and to explore candidate biomarkers predictive of response to SY-5609. Methods: This is a multi-center, open-label Phase 1 trial expected to enroll approximately 60 adult patients with select advanced solid tumors for which standard treatment is no longer effective. The dose escalation phase of the trial is open to adult patients with ovarian, breast, colorectal, or lung cancer, and patients with any solid tumor histology with molecular evidence of deregulated RB cell cycle control. SY-5609 is being administered orally once daily, for each 4-week cycle. Initially, patients will be enrolled into single-patient accelerated titration cohorts; subsequent cohorts will transition to a 3 + 3 design. Following completion of DLT evaluation at a given dose level, additional patients may be enrolled at that dose to further characterize safety, PK, PD, and early clinical activity. Data from this trial will support dose selection for planned evaluations of antitumor activity of SY-5609 as a single agent and in combination. Clinical trial information: NCT04247126 .
如何搞好支气管哮喘患者系统教育和管理
Authors: 何权瀛, 母双, 余兵, 崔月莉, 王悦真
Journal: BMJ (2007)

支气管哮喘是一种慢性呼吸道疾病,与许多其他慢性病一样,至今我们缺少彻底根治的办法,因此需要进行长期防控.这就需要广大哮喘患者与医护人员长期密切配合,所以搞好哮喘教育管理工作是哮喘防控工作中的一个十分重要的组成部分,是提高支气管哮喘防控水平的重要基础。
Correspondence to “Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments”
Authors: Tuomas Jartti, Hermelijn H. Smits, Klaus Bønnelykke, Ozlem Cavkaytar, Varpu Elenius, Jon R. Konradsen, Heidi Makrinioti, Jakob Stokholm, Gunilla Hedlin, Nikolaos Papadopoulos, Marek Ruszczynski, Klaudia Ryczaj, Bianca Schaub, Jürgen Schwarze, Wojciech Feleszko
Journal: Allergy (2020)

The authors have no conflict of interest in connection with this manuscript.
Research advances of pancreatic fatty infiltration
Authors: Dan Wang, Dongling Teng, Guotao Lu, Zhihui Tong, Yanbing Ding
Journal: BMJ (2018)

Pancreatic fatty infiltration is defined as the deposition of excess adipose tissue (mainly consisting of triacylglyceride) in the pancreas.Epidemiological studies have revealed that the prevalence of pancreatic fatty infiltration is high, but the research is still at a preliminary stage and there is no consensus on the relevant pathophysiological mechanisms so far. The diagnosis of pancreatic fatty infiltration relies on histopathologic examination and imaging techniques. This article reviews the recent research advances on the pancreatic fat infiltration in order to improve our understanding of the disease.


Key words: 
Obesity; Metabolic syndrome; Type 2 diabetes mellitus; Pancreatic fatty infiltration; Fatty liver disease
Cause analysis of high job burnout among staffs at community health service centers
Authors: Yan Ma
Journal: BMJ (2012)

To explore the current status of job burnout among 1210 staffs at local community health stations and analyze its influencing factors with multiple logistic regression analysis.The regression model of high emotional exhaustion had statistical significance (SE =0.070,P =0.000).The possibility of high emotional exhaustion was negatively correlated with the satisfaction of organizational commitment,rules and regulations,cooperation between colleagues,satisfaction of job nature and family supports.And it had a positive correlation with supports from family and colleagues and satisfaction of welfare.The regression model of high depersonlization had statistical significance (SE =0.072,P =0.000).The possibility of high depersonlization had a negative correlation with organizational commitment,cooperation between colleagues,satisfaction of job nature and smooth communications with leaders and family.And it was positively correlated with compensation,promotion,satisfaction of welfare and smooth inter-colleague communications.The regression model of highly reduced personal accomplishment had statistical significance (SE =0.061,P =0.000).The possibility of highly reduced personal accomplishment had a negative correlation with satisfaction of superiors,job category and communication,age,smooth communications with leaders and family.And it was positively correlated with satisfaction of compensation.

Key words: 
Fatigue;  Community health services
TCR-engineered T-cell therapy through personalized identification of CDR3 clonotypes.
Authors: Zishan Zhou, Yue Pu, Shanshan Xiao, Ping Wang, Yang Yu, Rui Lin, Tao Wang, Shun Chang Jiao
Journal: Journal of Clinical Oncology (2020)

e15021 Background: T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancers. Unlike many shared tumor-specific antigens, such as melanoma-associated antigen (MAGE)-A3, MAGE-A4, and New York esophageal squamous cell carcinoma (NY-ESO)-1, neoantigen has garnered much attention as a potential precision immunotherapy. Personalized neoantigen selection serves a broader and more precision future for cancer patients. Methods: Dendritic cells (DCs) derived from adherent monocytes were pulsed with mixed peptides during the maturation phase. CD8+ cells positively selected from PBMCs were incubated with washed DCs. After 21day culture in X-VIVO medium with IL-7 and IL-15, cells were harvested and stimulated with peptides for 6 h. CD137+ cells were sorted by flow cytometric and immediately processed using the 10x Genomic Chromium Single Cell 5' Library &amp; Gel Bead Kit and Chromium Single Cell V(D)J Enrichment Kit. The T-cell TCR libraries were constructed and sequenced on the Illumina HiSeq X Ten platform. The sequencing reads were aligned to the hg38 human reference genome and analyzed using the 10x Genomics Cell Ranger pipeline. The paired TCR α and β chain sequence of each cell was demonstrated with V(D)J analysis. TCR-T cells were constructed using the information of neoantigen specific TCR, and infused to patients. Results: Two patients were treated with the personalized TCR-T treatment. At the first stage, specialized immune cells were harvested and proceeded to single-cell TCR profiling. Then, the single cell sequencing of the first patient's sample revealed the top five neoantigen specific TCR CDR3 clonotypes with the proportion of 25%, 7.67%, 4.81%, 2.79%, and 2.54%, respectively. Similarly, the other patient had the top five TCR CDR3 sequenced with the proportion of 13.38%, 7.04%, 4.21%, 2.83%, and 1.94%, respectively. The results demonstrated that both patients had one or two dominant CDR3 clonotypes, which might reflect the strength of neoantigen in vivo. At the third stage, TCR-T cells were constructed, and infused to the patients. The clinical outcome will be evaluated in the near future. Conclusions: We have generated a pipeline for a highly personalized cancer therapy using TCR-engineered T cells. Although some questions remain to be answered, this novel approach may result in better clinical responses in future treatment.
Clinical analysis of screening for gestational diabetes mellitus in 945 pregnant women with 50 g glucose challenge test
Authors: 蔡晓频, 杨文英, 杨兆军
Journal: BMJ (2005)

目的 探讨妊娠糖尿病的临床特点及其相关因素.方法采用两种妊娠糖尿病诊断标准(世界卫生组织标准和Carpenter/Coustan标准)回顾性分析近1年在我院进行产前检查并行50 g葡萄糖负荷试验(GCT)的945例孕妇的临床资料.结果 945例孕妇GCT异常率为35.8%(338/945),228例GCT异常者中妊娠糖尿病发生率为44.7%(102/228,世界卫生组织标准).两种标准诊断的妊娠糖尿病孕妇与GCT正常的孕妇相比,年龄较大,孕前体重指数较高,孕初期体重增长较快,孕初期空腹血糖较高,糖尿病家族史阳性率较高.约孕30周时行75 g口服葡萄糖耐量试验结果显示,妊娠糖尿病孕妇较妊娠期正常糖耐量孕妇胰岛素敏感性下降,且胰岛素分泌高峰明显延迟.logistic回归分析显示,孕妇年龄、孕前体重指数、孕初期体重增长、孕初期空腹血糖与妊娠糖尿病发生呈正相关.结论妊娠糖尿病孕妇与非妊娠糖尿病孕妇比较,年龄较大,孕前体重指数较高,孕初期体重增长较快,孕初期空腹血糖较高,糖尿病家族史阳性率较高,胰岛素抵抗更重.对于具有妊娠糖尿病危险因素者,应在孕早期进行空腹血糖的筛查,以尽早诊断和治疗。
Taxane induced pulmonary toxicity in breast cancer.
Authors: Hrishi Varayathu, Hephzibah Sara Mathew, Vinu Sarathy, Beulah Elsa Thomas, Santosh Elluru Kumar, Nitheesha Reddy, Suhail Sayeed Mufti, Lalnun Puii, Lalram Sangi, Smruthy Ann Mathew, Samuel Luke Koramati, Dinesh S, Shivakumar Swamy, Radheshyam Naik, Basavalinga Sadasivaiah Ajaikumar
Journal: Journal of Clinical Oncology (2020)

e15522 Background: Taxanes are an integral part of chemotherapy for a broad range of tumor types. The usual toxicities associated with Taxane use are peripheral neuropathy, myelosuppression and musculoskeletal adverse effects. Very few studies have reported taxane induced pulmonary toxicity objectively. In our study we explored Taxane induced pulmonary toxicity based on discrete CT findings. Methods: 40 non-smokers diagnosed with Her-2 negative breast cancer who received Taxane monotherapy from 2017 to 2018 were retrospectively analyzed for pre and post therapy CT changes. Following CT findings were considered significant as pulmonary toxicity; (a) Nonspecific area with ground-glass attenuation, (b) multifocal areas of airspace consolidation, (c) patchy distribution of ground-glass attenuation accompanied by interlobular septal thickening and (d) extensive bilateral ground-glass attenuation or airspace consolidations with traction bronchiectasis. The CT findings were assessed independently by two radiologists and one pulmonologist. Results: Our study showed that 5 patients (12.5%) developed pulmonary changes on chest CT post Taxane therapy as summarized in Table. Conclusions: Our study shows that taxane has more potential to induce pulmonary toxicity than reported in present literature. Given that taxanes are the most widely used chemotherapy, it is of utmost necessity to be cognizant of this under-reported potentially fatal adverse effect in a large population. Further studies should be conducted to better understand the true potential, mechanisms and patterns of taxanes induced pulmonary toxicity. [Table: see text]
Ruxolitinib (RUX) retreatment in patients (Pts) with myelofibrosis (MF): Real-world evidence on pt characteristics and outcomes.
Authors: Naveen Pemmaraju, Jingbo Yu, Shreekant Parasuraman, Dilan Paranagama, Jonathan Kish, Jay Visaria, Mukul Singhal, Srdan Verstovsek, Aaron Thomas Gerds
Journal: Journal of Clinical Oncology (2020)

e19535 Background: RUX is a JAK1/JAK2 inhibitor FDA-approved for treatment (tx) of int/high risk MF. In the COMFORT studies, RUX reduced spleen volume in pts with MF (primary endpoint), with a median time to response of 3 mo. Case reports and clinical studies have shown some pts’ symptoms and/or splenomegaly improve upon RUX reinitiation after interruption. In the era of novel JAK inhibitors (JAKi), dose optimization and identifying indicators for tx changes remain major challenges. This study describes tx patterns and clinical outcomes of pts with MF with RUX interruption and retreatment in community-based clinical practices. Methods: Two independent patient care data sources were queried (not directly compared): (1) Cardinal Health Oncology Provider Extended Network (OPEN), (2) HealthCore Integrated Research Environment (HIRE); retrospective review of medical charts was conducted. Rigorous entry criteria for this analysis included: age ≥18 y; primary MF (PMF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF diagnosis between 1/1/2012–12/31/2016 (OPEN) or 1/2013–11/2017 (HIRE); use of RUX for MF; and documented physician-directed RUX interruption. MF-related symptoms, splenomegaly, and tx dose and patterns were analyzed. Results: 26 pts met entry criteria (Table). Pre-interruption median (IQR) RUX tx duration was 123 (57–391, OPEN) and 110 (37–148, HIRE) days; 50% had tx interruption within 3 mo. Most interruptions were for adverse events (AEs; 50% and 71%, respectively), followed by (in OPEN) alternative tx (17%), disease progression (8%), no response (8%), or loss of response (8%). After restarting RUX, median (IQR) retreatment duration was 196 (54–553) and 166 (108–262) days, respectively. Symptoms improved in 45% and 43% of evaluable pts, respectively, and spleen size improved in 40% and 33%. Conclusions: Consistent with previous reports, MF symptoms and spleen size improved with RUX retreatment in some pts. While RUX was discontinued for various reasons, one reason for clinical improvements upon reinitiation may be that tx was discontinued before deriving full JAKi benefit. Future studies are warranted investigating JAKi tx sequencing and reinitiation. [Table: see text]
顽固性高血压的处理
Authors: 吴海云
Journal: BMJ (2012)

顽固性高血压,指至少采用了3种降压药物(包括利尿剂)治疗,且剂量足够,但血压仍未降到目标水平.对这类患者,先要考虑血压测量是否正确,其次要仔细了解服药的依从性,寻找引起血压升高的其他因素,再认真排除继发性高血压的可能.通过调整用药,绝大多数高血压患者都能控制达标。